Netherlands
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.87 (0.70 - 1.04) | 2019 | Modelled | IHME |
| 0.88 (0.71 - 1.05) | 2018 | Modelled | IHME |
| 0.9 (0.72 - 1.07) | 2017 | Modelled | IHME |
| 0.91 (0.75 - 1.08) | 2016 | Modelled | IHME |
| 0.92 (0.77 - 1.09) | 2015 | Modelled | IHME |
| 0.92 (0.76 - 1.08) | 2014 | Modelled | IHME |
| 0.92 (0.76 - 1.08) | 2013 | Modelled | IHME |
| 0.91 (0.75 - 1.08) | 2012 | Modelled | IHME |
| 0.91 (0.75 - 1.08) | 2011 | Modelled | IHME |
| 0.91 (0.73 - 1.08) | 2010 | Modelled | IHME |
| 0.9 (0.74 - 1.07) | 2009 | Modelled | IHME |
| 0.9 (0.74 - 1.06) | 2008 | Modelled | IHME |
| 0.89 (0.74 - 1.05) | 2007 | Modelled | IHME |
| 0.89 (0.73 - 1.05) | 2006 | Modelled | IHME |
| 0.89 (0.73 - 1.05) | 2005 | Modelled | IHME |
| 0.89 (0.74 - 1.05) | 2004 | Modelled | IHME |
| 0.9 (0.75 - 1.06) | 2003 | Modelled | IHME |
| 0.91 (0.76 - 1.08) | 2002 | Modelled | IHME |
| 0.92 (0.77 - 1.09) | 2001 | Modelled | IHME |
| 0.93 (0.77 - 1.10) | 2000 | Modelled | IHME |
| 0.93 (0.77 - 1.10) | 1999 | Modelled | IHME |
| 0.92 (0.76 - 1.09) | 1998 | Modelled | IHME |
| 0.92 (0.76 - 1.09) | 1997 | Modelled | IHME |
| 0.91 (0.76 - 1.08) | 1996 | Modelled | IHME |
| 0.91 (0.75 - 1.09) | 1995 | Modelled | IHME |
| 0.91 (0.76 - 1.08) | 1994 | Modelled | IHME |
| 0.92 (0.75 - 1.09) | 1993 | Modelled | IHME |
| 0.92 (0.76 - 1.09) | 1992 | Modelled | IHME |
| 0.93 (0.77 - 1.11) | 1991 | Modelled | IHME |
| 0.94 (0.77 - 1.13) | 1990 | Modelled | IHME |
| 0.34 (0.22 - 0.47) | 2016 | Survey/reported | Koopsen J et al, 2019 |
| 0.2 (0.10 - 0.40) | 2007 | Survey/reported | Hahne SJM et al, 2012 |
| 0.09 (0.07 - 0.11) | 2015 | Modelled | WHO |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.06 (0.04 - 0.07) | 2019 | Modelled | IHME |
| 0.06 (0.04 - 0.08) | 2018 | Modelled | IHME |
| 0.06 (0.04 - 0.08) | 2017 | Modelled | IHME |
| 0.07 (0.05 - 0.09) | 2016 | Modelled | IHME |
| 0.08 (0.06 - 0.11) | 2015 | Modelled | IHME |
| 0.12 (0.08 - 0.16) | 2014 | Modelled | IHME |
| 0.18 (0.12 - 0.24) | 2013 | Modelled | IHME |
| 0.25 (0.17 - 0.34) | 2012 | Modelled | IHME |
| 0.31 (0.21 - 0.43) | 2011 | Modelled | IHME |
| 0.34 (0.22 - 0.47) | 2010 | Modelled | IHME |
| 0.34 (0.23 - 0.46) | 2009 | Modelled | IHME |
| 0.34 (0.23 - 0.46) | 2008 | Modelled | IHME |
| 0.34 (0.23 - 0.45) | 2007 | Modelled | IHME |
| 0.34 (0.23 - 0.45) | 2006 | Modelled | IHME |
| 0.34 (0.23 - 0.44) | 2005 | Modelled | IHME |
| 0.35 (0.24 - 0.46) | 2004 | Modelled | IHME |
| 0.37 (0.25 - 0.49) | 2003 | Modelled | IHME |
| 0.4 (0.27 - 0.52) | 2002 | Modelled | IHME |
| 0.42 (0.28 - 0.55) | 2001 | Modelled | IHME |
| 0.43 (0.28 - 0.56) | 2000 | Modelled | IHME |
| 0.43 (0.28 - 0.56) | 1999 | Modelled | IHME |
| 0.42 (0.27 - 0.56) | 1998 | Modelled | IHME |
| 0.42 (0.27 - 0.56) | 1997 | Modelled | IHME |
| 0.42 (0.27 - 0.56) | 1996 | Modelled | IHME |
| 0.42 (0.27 - 0.55) | 1995 | Modelled | IHME |
| 0.42 (0.27 - 0.55) | 1994 | Modelled | IHME |
| 0.42 (0.27 - 0.55) | 1993 | Modelled | IHME |
| 0.42 (0.27 - 0.55) | 1992 | Modelled | IHME |
| 0.42 (0.28 - 0.56) | 1991 | Modelled | IHME |
| 0.43 (0.29 - 0.58) | 1990 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2015 | Modelled | WHO |
Showing out of
Show more
Men who have sex with men (MSM)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.48 | 2017 | Survey/reported | ECDC Monitoring Report |
| 0.83 | 2017 | Survey/reported | ECDC Monitoring Report |
Showing out of
Show more
Pregnant women
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.3 (0.30 - 0.40) | 2016 | Modelled | ECDC |
| 0.3 (0.30 - 0.40) | 2006 | Survey/reported | Op de Coul EL et al, 2011 |
| 0.3 (0.30 - 0.40) | 2007 | Survey/reported | Op de Coul EL et al, 2011 |
| 0.4 (0.40 - 0.40) | 2008 | Survey/reported | Op de Coul EL et al, 2011 |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 1.65 (1.27 - 2.11) | 2019 | Modelled | IHME |
| 1.64 (1.26 - 2.10) | 2018 | Modelled | IHME |
| 1.64 (1.25 - 2.08) | 2017 | Modelled | IHME |
| 1.62 (1.25 - 2.08) | 2016 | Modelled | IHME |
| 1.58 (1.22 - 2.03) | 2015 | Modelled | IHME |
| 1.56 (1.20 - 1.99) | 2014 | Modelled | IHME |
| 1.58 (1.22 - 2.02) | 2013 | Modelled | IHME |
| 1.61 (1.25 - 2.06) | 2012 | Modelled | IHME |
| 1.61 (1.24 - 2.05) | 2011 | Modelled | IHME |
| 1.62 (1.25 - 2.05) | 2010 | Modelled | IHME |
| 1.61 (1.24 - 2.04) | 2009 | Modelled | IHME |
| 1.61 (1.24 - 2.05) | 2008 | Modelled | IHME |
| 1.6 (1.23 - 2.05) | 2007 | Modelled | IHME |
| 1.61 (1.24 - 2.10) | 2006 | Modelled | IHME |
| 1.63 (1.25 - 2.11) | 2005 | Modelled | IHME |
| 1.67 (1.28 - 2.16) | 2004 | Modelled | IHME |
| 1.74 (1.34 - 2.26) | 2003 | Modelled | IHME |
| 1.68 (1.29 - 2.18) | 2002 | Modelled | IHME |
| 1.63 (1.26 - 2.11) | 2001 | Modelled | IHME |
| 1.6 (1.24 - 2.07) | 2000 | Modelled | IHME |
| 1.57 (1.21 - 2.02) | 1999 | Modelled | IHME |
| 1.52 (1.17 - 1.96) | 1998 | Modelled | IHME |
| 1.49 (1.15 - 1.93) | 1997 | Modelled | IHME |
| 1.48 (1.14 - 1.93) | 1996 | Modelled | IHME |
| 1.46 (1.12 - 1.89) | 1995 | Modelled | IHME |
| 1.42 (1.09 - 1.84) | 1994 | Modelled | IHME |
| 1.4 (1.07 - 1.82) | 1993 | Modelled | IHME |
| 1.35 (1.03 - 1.75) | 1992 | Modelled | IHME |
| 1.32 (1.02 - 1.70) | 1991 | Modelled | IHME |
| 1.29 (0.99 - 1.67) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 283 (218 - 362) | 2019 | Modelled | IHME |
| 281 (216 - 359) | 2018 | Modelled | IHME |
| 279 (213 - 355) | 2017 | Modelled | IHME |
| 276 (212 - 353) | 2016 | Modelled | IHME |
| 268 (206 - 343) | 2015 | Modelled | IHME |
| 262 (202 - 335) | 2014 | Modelled | IHME |
| 265 (205 - 339) | 2013 | Modelled | IHME |
| 270 (208 - 345) | 2012 | Modelled | IHME |
| 268 (206 - 342) | 2011 | Modelled | IHME |
| 268 (207 - 341) | 2010 | Modelled | IHME |
| 267 (205 - 337) | 2009 | Modelled | IHME |
| 265 (204 - 338) | 2008 | Modelled | IHME |
| 262 (201 - 336) | 2007 | Modelled | IHME |
| 264 (203 - 343) | 2006 | Modelled | IHME |
| 266 (204 - 344) | 2005 | Modelled | IHME |
| 272 (208 - 351) | 2004 | Modelled | IHME |
| 282 (216 - 365) | 2003 | Modelled | IHME |
| 271 (207 - 350) | 2002 | Modelled | IHME |
| 261 (201 - 338) | 2001 | Modelled | IHME |
| 254 (197 - 329) | 2000 | Modelled | IHME |
| 247 (191 - 320) | 1999 | Modelled | IHME |
| 239 (183 - 308) | 1998 | Modelled | IHME |
| 233 (180 - 301) | 1997 | Modelled | IHME |
| 229 (176 - 299) | 1996 | Modelled | IHME |
| 225 (173 - 292) | 1995 | Modelled | IHME |
| 218 (167 - 282) | 1994 | Modelled | IHME |
| 213 (164 - 277) | 1993 | Modelled | IHME |
| 204 (157 - 265) | 1992 | Modelled | IHME |
| 198 (153 - 255) | 1991 | Modelled | IHME |
| 193 (148 - 249) | 1990 | Modelled | IHME |
| 484 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 11 (8 - 16) | 2019 | Modelled | IHME |
| 11 (8 - 16) | 2018 | Modelled | IHME |
| 11 (8 - 16) | 2017 | Modelled | IHME |
| 11 (8 - 16) | 2016 | Modelled | IHME |
| 11 (8 - 16) | 2015 | Modelled | IHME |
| 12 (8 - 17) | 2014 | Modelled | IHME |
| 12 (8 - 17) | 2013 | Modelled | IHME |
| 12 (8 - 17) | 2012 | Modelled | IHME |
| 12 (8 - 17) | 2011 | Modelled | IHME |
| 12 (8 - 17) | 2010 | Modelled | IHME |
| 12 (8 - 17) | 2009 | Modelled | IHME |
| 12 (8 - 17) | 2008 | Modelled | IHME |
| 12 (8 - 17) | 2007 | Modelled | IHME |
| 12 (8 - 17) | 2006 | Modelled | IHME |
| 12 (8 - 17) | 2005 | Modelled | IHME |
| 12 (8 - 17) | 2004 | Modelled | IHME |
| 12 (8 - 17) | 2003 | Modelled | IHME |
| 12 (8 - 17) | 2002 | Modelled | IHME |
| 12 (8 - 17) | 2001 | Modelled | IHME |
| 12 (9 - 17) | 2000 | Modelled | IHME |
| 12 (9 - 17) | 1999 | Modelled | IHME |
| 12 (9 - 17) | 1998 | Modelled | IHME |
| 12 (9 - 17) | 1997 | Modelled | IHME |
| 12 (9 - 18) | 1996 | Modelled | IHME |
| 12 (9 - 18) | 1995 | Modelled | IHME |
| 12 (9 - 18) | 1994 | Modelled | IHME |
| 12 (9 - 18) | 1993 | Modelled | IHME |
| 12 (9 - 18) | 1992 | Modelled | IHME |
| 12 (9 - 18) | 1991 | Modelled | IHME |
| 12 (9 - 18) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 92 | 2018 | Survey/reported | WHO/UNICEF |
| 92 | 2017 | Survey/reported | WHO/UNICEF |
| 93 | 2016 | Survey/reported | WHO/UNICEF |
| 94 | 2015 | Survey/reported | WHO/UNICEF |
| 94 | 2014 | Survey/reported | WHO/UNICEF |
| 51 | 2013 | Survey/reported | WHO/UNICEF |
| 20 | 2012 | Survey/reported | WHO/UNICEF |
| 20 | 2011 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 414 (170 - 659) | 2014 | Survey/reported | van Laar M et al, 2014 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.48 (0.40 - 0.59) | 2019 | Modelled | IHME |
| 0.48 (0.39 - 0.58) | 2018 | Modelled | IHME |
| 0.47 (0.39 - 0.58) | 2017 | Modelled | IHME |
| 0.47 (0.38 - 0.57) | 2016 | Modelled | IHME |
| 0.46 (0.38 - 0.56) | 2015 | Modelled | IHME |
| 0.44 (0.36 - 0.53) | 2014 | Modelled | IHME |
| 0.4 (0.32 - 0.48) | 2013 | Modelled | IHME |
| 0.35 (0.29 - 0.42) | 2012 | Modelled | IHME |
| 0.32 (0.26 - 0.38) | 2011 | Modelled | IHME |
| 0.3 (0.25 - 0.36) | 2010 | Modelled | IHME |
| 0.3 (0.25 - 0.36) | 2009 | Modelled | IHME |
| 0.31 (0.25 - 0.37) | 2008 | Modelled | IHME |
| 0.31 (0.26 - 0.37) | 2007 | Modelled | IHME |
| 0.32 (0.27 - 0.38) | 2006 | Modelled | IHME |
| 0.33 (0.28 - 0.39) | 2005 | Modelled | IHME |
| 0.36 (0.30 - 0.43) | 2004 | Modelled | IHME |
| 0.42 (0.34 - 0.50) | 2003 | Modelled | IHME |
| 0.48 (0.39 - 0.58) | 2002 | Modelled | IHME |
| 0.53 (0.42 - 0.65) | 2001 | Modelled | IHME |
| 0.55 (0.44 - 0.68) | 2000 | Modelled | IHME |
| 0.54 (0.43 - 0.66) | 1999 | Modelled | IHME |
| 0.5 (0.41 - 0.62) | 1998 | Modelled | IHME |
| 0.47 (0.38 - 0.57) | 1997 | Modelled | IHME |
| 0.43 (0.35 - 0.53) | 1996 | Modelled | IHME |
| 0.41 (0.34 - 0.51) | 1995 | Modelled | IHME |
| 0.41 (0.33 - 0.50) | 1994 | Modelled | IHME |
| 0.4 (0.33 - 0.49) | 1993 | Modelled | IHME |
| 0.4 (0.33 - 0.49) | 1992 | Modelled | IHME |
| 0.4 (0.32 - 0.49) | 1991 | Modelled | IHME |
| 0.4 (0.32 - 0.49) | 1990 | Modelled | IHME |
Showing out of
Show more
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.16 (0.06 - 0.27) | 2019 | Survey/reported | Koopsen J et al, 2019 |
| 0.1 (0 - 0.20) | 2007 | Survey/reported | Vriend HJ et al, 2013 |
| 0.2 (0.10 - 0.40) | 2014 | Modelled | Gower et al, 2014 |
Showing out of
Show more
Men who have sex with men (MSM)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.3 (0.80 - 1.90) | 2003 | Survey/reported | van de Laar TJ et al , 2007 |
| 0.7 (0.10 - 1.90) | 2007 | Survey/reported | Van Rooijen MS et al , 2013 |
| 4.8 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 55.3 (49.70 - 60.90) | 2017 | Modelled | Degenhardt L et al, 2017 |
| 39.3 | 2013 | Survey/reported | EMCDDA |
Showing out of
Show more
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 3.62 (2.86 - 4.43) | 2019 | Modelled | IHME |
| 3.56 (2.81 - 4.36) | 2018 | Modelled | IHME |
| 3.52 (2.76 - 4.31) | 2017 | Modelled | IHME |
| 3.5 (2.80 - 4.29) | 2016 | Modelled | IHME |
| 3.4 (2.69 - 4.19) | 2015 | Modelled | IHME |
| 3.29 (2.59 - 4.05) | 2014 | Modelled | IHME |
| 3.24 (2.58 - 3.99) | 2013 | Modelled | IHME |
| 3.2 (2.57 - 3.95) | 2012 | Modelled | IHME |
| 3.09 (2.46 - 3.81) | 2011 | Modelled | IHME |
| 3.03 (2.40 - 3.72) | 2010 | Modelled | IHME |
| 2.99 (2.38 - 3.67) | 2009 | Modelled | IHME |
| 2.96 (2.37 - 3.63) | 2008 | Modelled | IHME |
| 2.91 (2.33 - 3.58) | 2007 | Modelled | IHME |
| 2.91 (2.30 - 3.59) | 2006 | Modelled | IHME |
| 2.9 (2.29 - 3.60) | 2005 | Modelled | IHME |
| 2.95 (2.33 - 3.66) | 2004 | Modelled | IHME |
| 3.04 (2.41 - 3.77) | 2003 | Modelled | IHME |
| 2.95 (2.33 - 3.65) | 2002 | Modelled | IHME |
| 2.85 (2.27 - 3.56) | 2001 | Modelled | IHME |
| 2.78 (2.21 - 3.50) | 2000 | Modelled | IHME |
| 2.73 (2.17 - 3.39) | 1999 | Modelled | IHME |
| 2.66 (2.12 - 3.29) | 1998 | Modelled | IHME |
| 2.61 (2.09 - 3.22) | 1997 | Modelled | IHME |
| 2.56 (2.05 - 3.17) | 1996 | Modelled | IHME |
| 2.53 (2.01 - 3.14) | 1995 | Modelled | IHME |
| 2.46 (1.95 - 3.05) | 1994 | Modelled | IHME |
| 2.42 (1.92 - 3) | 1993 | Modelled | IHME |
| 2.33 (1.86 - 2.91) | 1992 | Modelled | IHME |
| 2.27 (1.81 - 2.83) | 1991 | Modelled | IHME |
| 2.23 (1.77 - 2.78) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 621 (491 - 760) | 2019 | Modelled | IHME |
| 609 (480 - 746) | 2018 | Modelled | IHME |
| 599 (471 - 734) | 2017 | Modelled | IHME |
| 595 (476 - 728) | 2016 | Modelled | IHME |
| 575 (455 - 708) | 2015 | Modelled | IHME |
| 554 (437 - 683) | 2014 | Modelled | IHME |
| 543 (433 - 670) | 2013 | Modelled | IHME |
| 535 (430 - 661) | 2012 | Modelled | IHME |
| 516 (410 - 635) | 2011 | Modelled | IHME |
| 503 (398 - 618) | 2010 | Modelled | IHME |
| 495 (394 - 607) | 2009 | Modelled | IHME |
| 487 (391 - 598) | 2008 | Modelled | IHME |
| 478 (382 - 587) | 2007 | Modelled | IHME |
| 476 (377 - 587) | 2006 | Modelled | IHME |
| 473 (373 - 587) | 2005 | Modelled | IHME |
| 479 (378 - 594) | 2004 | Modelled | IHME |
| 492 (389 - 609) | 2003 | Modelled | IHME |
| 474 (375 - 586) | 2002 | Modelled | IHME |
| 456 (363 - 569) | 2001 | Modelled | IHME |
| 442 (351 - 556) | 2000 | Modelled | IHME |
| 431 (343 - 536) | 1999 | Modelled | IHME |
| 417 (333 - 516) | 1998 | Modelled | IHME |
| 407 (326 - 502) | 1997 | Modelled | IHME |
| 398 (317 - 492) | 1996 | Modelled | IHME |
| 390 (311 - 484) | 1995 | Modelled | IHME |
| 376 (299 - 467) | 1994 | Modelled | IHME |
| 368 (292 - 457) | 1993 | Modelled | IHME |
| 352 (281 - 441) | 1992 | Modelled | IHME |
| 342 (272 - 426) | 1991 | Modelled | IHME |
| 332 (264 - 415) | 1990 | Modelled | IHME |
| 634 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 35 (27 - 44) | 2019 | Modelled | IHME |
| 35 (26 - 44) | 2018 | Modelled | IHME |
| 35 (26 - 44) | 2017 | Modelled | IHME |
| 35 (26 - 44) | 2016 | Modelled | IHME |
| 35 (26 - 43) | 2015 | Modelled | IHME |
| 35 (26 - 43) | 2014 | Modelled | IHME |
| 34 (26 - 43) | 2013 | Modelled | IHME |
| 34 (26 - 43) | 2012 | Modelled | IHME |
| 34 (26 - 43) | 2011 | Modelled | IHME |
| 34 (26 - 42) | 2010 | Modelled | IHME |
| 34 (26 - 42) | 2009 | Modelled | IHME |
| 34 (26 - 42) | 2008 | Modelled | IHME |
| 34 (26 - 42) | 2007 | Modelled | IHME |
| 34 (26 - 42) | 2006 | Modelled | IHME |
| 34 (26 - 42) | 2005 | Modelled | IHME |
| 34 (26 - 42) | 2004 | Modelled | IHME |
| 34 (25 - 42) | 2003 | Modelled | IHME |
| 34 (25 - 42) | 2002 | Modelled | IHME |
| 34 (25 - 42) | 2001 | Modelled | IHME |
| 34 (25 - 42) | 2000 | Modelled | IHME |
| 34 (25 - 42) | 1999 | Modelled | IHME |
| 34 (26 - 42) | 1998 | Modelled | IHME |
| 34 (26 - 42) | 1997 | Modelled | IHME |
| 34 (26 - 42) | 1996 | Modelled | IHME |
| 34 (25 - 42) | 1995 | Modelled | IHME |
| 34 (26 - 42) | 1994 | Modelled | IHME |
| 34 (25 - 43) | 1993 | Modelled | IHME |
| 34 (25 - 43) | 1992 | Modelled | IHME |
| 34 (26 - 43) | 1991 | Modelled | IHME |
| 34 (25 - 43) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 300 (170 - 659) | 2014 | Survey/reported | van Laar M et al, 2014 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
HBV (HBsAg+)
0.87
(%)
2019
(0.7 - 1.04(%))
IHME
HCV (RNA/cAg+)
0.48
(%)
2019
(0.4 - 0.59(%))
IHME
Survey/surveillance
HBV (HBsAg+)
0.34
(%)
2016
(0.22 - 0.47(%))
Koopsen J et al, 2019
HCV (anti-HCV)
0.16
(%)
2019
(0.06 - 0.27(%))
Koopsen J et al, 2019
Hepatitis related deaths (national)
Modelled
HBV
283
2019
(218 - 362)
IHME
Survey/surveillance
No data available
HBV chart
Modelled
HCV
621
2019
(491 - 760)
IHME
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.06
(%)
2019, latest modelled
(0.04 - 0.07(%))
IHME
Prevalence PWID
HCV
39.30
(%)
2013, survey/surveillance
EMCDDA
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
HCV
414
2014
(170 - 659)
van Laar M et al, 2014
Eligible for HBV generic medicines
Eligible for HCV generic medicines